London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Get lost sing a g string! We all know we didnt get the usual speeding ticket rns. Only way is up from here. 50p plus today!
I don't believe everyone here knows what phase 2 means. It does not mean final approval as most people are aware so don't get carried away with outlandish price predictions. But good progress nonetheless.
I see the first RNS and oh dear, here we go, was expecting the usual 'we have noted the recent price movement etc etc, but no...positive instead. Then see the next 2 for price monitoring...already?! Never seen price monitoring this early in the day...going to be fun during the day. GLALTHs. :-)
Everyone knows it’s only phase 2...so no surprises then are there
Still only Phase II, right? So still a long way to approval if Stage III to come.
Positive RNS, they had to issue something re: the sp rise it seems and it shows that all is on course so a really positive RNS imo. Val201 results due in just a few days. All looking very strong for Val and a few more warrants exercised.
Terrier54,
I'm not disputing whether or not the RNS is a 'warning' - as you put it, I just wonder what lead you to think that.
I would be grateful if you could delineate.
Thank you
:o )
Can anyone advise me how the warrants were granted in thr first place? Did we have to request them or were they allocated automatically...great rns to confirm carry on speeding!!!!
Yes terrier they are warning us that all is well
Far from it Terrier, that's an endorsing sign IMHO.
But being prudent.
That's a warning sign from the company.
Careful.
I love the way the new Val is clear and efficient about it's progress.
It's going to be a very exciting next few days.
Just love this company, all on track.
London, UK 23 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in its share price and confirms as notified on 7 September 2020, it still expects to receive and notify the headline VAL 201 trial results by 30 September 2020 as stated in the half year results notified on 7 September 2020, extracts of which as set out below:-
"The Phase 1/2 clinical trial of VAL201 in the treatment of men with prostate cancer was closed to further recruitment on 27 January 2020, with recruitment standing at a total of 12 patients dosed across 5 cohorts. The dose escalation was carried out from 0.5 mg/kg up to 8 mg/kg with dosing being carried out once a week.
The trial considered the safety and tolerability of drug administration, alongside pharmacokinetics and disease impact. Although the COVID-19 pandemic lockdown initially cast concern on the time schedules for data verification processes, the project remains on track to release headline results within Q3 2020, which will provide basic details of safety, tolerability and disease impact. More detailed observations on the pharmacokinetics and complete summaries of patient demographics, biochemistry and study conduct will be available when the Clinical Study Report is completed in Q4 2020."
Following the placing announced on 23 July 2020 and the subsequent warrant exercises and block listing application announced on 19 August 2020 and the warrant update announced on 14 September 2020, the Company's current cash balance is circa £2 million.
Exercise of Warrant
The Company announces it has received a further notification for the exercise of a warrant over 200,000 ordinary shares in the Company at an exercise price of 12.5 pence per share providing the Company with proceeds of £25,000 ("Warrant Exercise").
Application will be made to the London Stock Exchange to admit the 200,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 28 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 58,789,423 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
Warrant Update
As announced on 14 September 2020, the Company confirms that the qualifying criteria for the accelerated exercise of the Broker Warrants, as announced on 4 May 2020, of achieving a closing price over 15p for 5 cons